EU/3/03/166

Table of contents

About

On 17 October 2003, orphan designation (EU/3/03/166) was granted by the European Commission to QuadraMed, United Kingdom, for eculizumab for the treatment of paroxysmal nocturnal haemoglobinuria.

The sponsorship was transferred to Alexion Europe SAS, France, in March 2006.

Eculizumab in treatment of paroxysmal nocturnal haemoglobinuria has been authorised in the EU as Soliris since 20 June 2007.

Key facts

Active substance
Eculizumab
Medicine name
Soliris
Disease / condition
Treatment of paroxysmal nocturnal haemoglobinuria
Date of decision
17/10/2003
Outcome
Positive
Orphan decision number
EU/3/03/166

Sponsor's contact details

Alexion Europe SAS
1-15, avenue Edouard Belin
92500 Rueil-Malmaison
France
Tel. +33 147323621
Fax +33 147102446
E-mail: medicalinformation.europe@alxn.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating